Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience
- 24 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical and Translational Oncology
- Vol. 23 (6), 1245-1252
- https://doi.org/10.1007/s12094-020-02515-3
Abstract
Background Cancer and cancer therapies have been associated with an increased incidence of venous thromboembolic events (VTE). However, the incidence of VTE in patients on immunotherapy has not been well characterized. The aim of this study was to assess the incidence of VTE in cancer patients receiving immunotherapy and ascertain its prognostic utility. Materials and methods We conducted a single-institution retrospective study, including all cancer patients treated with anti-Programmed cell Death 1 (PD-1), anti-Programmed cell Death Ligand-1 (PD-L1), anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4), a combination of anti-PD-1/anti-PD-L1 and anti-CTLA4 or a combination including any of these drugs with chemotherapy, antiangiogenic agents or both between June 2013 and April 2019 at La Paz University Hospital, Madrid (Spain). Results We selected 229 patients. VTE occurred in 16 of 229 patients (7%). VTE occurred more frequently in patients with lung cancer followed by melanoma. Female sex and melanoma were independently associated with an increased risk of VTE. 12 of 16 VTE (75%) were symptomatic. Progressive disease to immunotherapy [HR 31.60 (95% CI 11.44–87.22), p = 0.00], lung cancer [HR 2.55 (95% CI 1.34–4.86), p = 0.00] and melanoma [HR 2.42 (1.20–4.86), p = 0.01] were independently associated with shorter OS. VTE occurrence was not independently associated with shorter OS [HR 1.33 (95% CI 0.63–2.80), p = 0.44]. Conclusions The incidence of VTE in cancer patients receiving immunotherapy in our study appeared to be similar to the incidence previously reported in other series of cancer patients treated with systemic therapies. VTE occurrence did not correlate with the prognosis. Further and prospective studies are needed to derive definitive conclusions.Keywords
This publication has 29 references indexed in Scilit:
- Epidemiology of cancer-associated venous thrombosisBlood, 2013
- Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United StatesCancer, 2012
- Postoperative Venous Thromboembolism Predicts Survival in Cancer PatientsAnnals of Surgery, 2012
- Role of Tissue Factor in CancerJournal of Clinical Oncology, 2009
- Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolismCancer, 2009
- Epidemiology of cancer-related venous thromboembolismBest Practice & Research Clinical Haematology, 2009
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patientsAnnals of Oncology, 2007
- Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapyJournal of Thrombosis and Haemostasis, 2007
- Prognosis of Cancers Associated with Venous ThromboembolismThe New England Journal of Medicine, 2000